Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220115 · ClinicalTrials.gov registry record
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
A clinical trial of Sickle Cell Disease, sponsored by Novartis.
- Completed
- Registry status
- 498
- Enrollment target
- 20
- Study locations
NCT01220115 is a study of Sickle Cell Disease that has completed, run by Novartis. The registered enrollment target is 498 participants, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01220115, a study of Sickle Cell Disease, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 498 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
Conditions Studied
Study Locations (20)
Florida
- Broward Oncology Associates, P.A. - Fort Lauderdale
- Miami Children's Hospital - Miami
- Innovative Medical Research - Miami
- M.D. Anderson Cancer Center Orlando - Orlando
- All Children's Hospital - St. Petersburg
- Central Tampa Hematology and Oncology Associates - Tampa
- St. Joseph Children's Hospital - Tampa
California
- Children's Hospital Oakland (CHO) - Oakland
- Children's Hospital of Orange County Sickle Cell Disease Center - Orange
- Rady Children's Hopsital / UC San Diego University Hospital Sickle Cell Disease Center - San Diego
Illinois
- University of Illinois at Chicago, Dept of Pediatrics - Chicago
- Abington Hematology Oncology Associates, Inc - Oak Lawn
Louisiana
- Tulane University School of Medicine - New Orleans
- LSU Department of Pediatrics Children's Hospital - New Orleans
Maryland
- Johns Hopkins University Division of Hematology - Baltimore
- Oncology-Hematology Associates, P.A. - Clinton
Arkansas
- Hematology Oncology Services of Arkansas - Little Rock
Connecticut
- Hematology Oncology, P.C. - Stamford
District of Columbia
- Howard University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220115
The ClinicalTrials.gov registry entry for NCT01220115 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01220115 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01220115 about?
NCT01220115 is a clinical study titled "A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients". A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
What is the current status of trial NCT01220115?
This trial is currently completed. The enrollment target is 498 participants. The study started on 2010-01. Estimated completion is 2014-09.
What conditions does trial NCT01220115 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
Who is sponsoring clinical trial NCT01220115?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01220115 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.